

AMENDMENTS TO THE CLAIMS

1. (Currently amended) A method of qualifying the prostate cancer status in a subject comprising:

(a) measuring the amount of ~~[[of]]~~

Marker I: ~~having a molecular weight of about 7.808 kD~~ in a biological sample from the subject, and

(b) comparing the measured amount of Marker I to that of a control,

[[b)]] wherein a decrease in the amount of ~~the marker~~ Marker I as compared to a control is ~~correlated with~~ indicative that the subject has prostate cancer status.

2. (Original) The method of claim 1 further comprising:

(c) managing subject treatment based on the status.

3. (Original) The method of claim 2, wherein managing subject treatment is selected from ordering more tests, performing surgery, and taking no further action.

4. (Currently amended) The method of claim 2 further comprising:

(d) measuring ~~the marker~~ Marker I after subject management.

5-10. (Cancelled)

11. (Currently amended) The method of claim 1 wherein ~~the marker~~ Marker I is detected by mass spectrometry.

12. (Currently amended) The method of claim 1 wherein ~~the marker~~ Marker I is detected by capturing the marker on a biochip having an affinity surface and detecting the captured marker by SELDI.

13-77. (Cancelled)

78. (New) The method of claim 1, wherein Marker I has a molecular weight from 7.796 kDa to 7.820 kDa.